|
We call this August issue “Eyes – the Window to your Soul”. The team behind APBN is honoured to invite Associate Professor Ian Yeo Yew San from Singapore National Eye Centre as our guest editor. In his article, he talks about the controlled environment of a clinical trial can never be replicated in a real life clinical setting due to limited resources. Clinical trials are cornerstones of evidence-based medicine (EBM) but they are only one of the components in the complex landscape of healthcare practice. You can read more on “Clinical Trials in our Real World”.
Age Related Macula Degeneration (AMD) is a common eye disease among people aged 50 and above. AMD, as suggested by its name, occurs due to the damage of macula, the most sensitive part of retina in our eyes. This eye condition can be classified into early, intermediate and advanced stage and is the leading cause for gradual vision loss in many older people. An article in Features, written by Dr Anna Tan, discusses the current and emerging diagnostic (imaging) and therapeutic developments in AMD. The significant developments in imaging for this disease include optical coherence tomography (OCT), fundus autofluorescence (FAF) and adaptive optics. Also check out the articles from other clinicians and scientists to learn more about the international collaborations done to address healthcare issues due to aging.
In Spotlights, APBN interviews Dr Allen Lai, the Senior Vice President of ACT Genomics, on how genetic testing can help in figuring customised and more effective treatment for cancer patients. We also feature several distinguished scientists from Commonwealth countries about agricultural biotechnology, stem cell research and burdens of malnutrition, respectively. If you are interested in robotics, it would be good to know that robots might be potentially used in eye surgery to help overcome challenges in ophthalmology in coming years.
Hope you enjoy reading APBN and take initiatives to protect and care for your eyes.
Thank you.
|
